ArticleJACC. Case reports2026
Val142Ile ATTR Cardiomyopathy: From Disease Progression to Clinical Stabilization With Vutrisiran.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVal142Ile hereditary transthyretin amyloidosis (hATTR) is an underrecognized cause of heart failure with preserved ejection fraction (HFpEF) in older individuals of African ancestry. CASE SUMMARY: An 83-year-old woman with persistent atrial fibrillation, chronic obstructive pulmonary disease, and HFpEF presented with progressive exertional dyspnea. Transthoracic echocardiography demonstrated preserved ejection fraction with increased ventricular wall thickness, biatrial enlargement, and pulmonary hypertension. Technetium-99 m pyrophosphate imaging showed grade 3 myocardial uptake, and monoclonal protein studies were negative. Genetic testing confirmed the TTR c.424G > A (p.Val142Ile) variant. Tafamidis was initiated, but worsening symptoms, declining transthyretin (prealbumin), and rising natriuretic peptides suggested disease progression. Therapy was escalated to the RNA-silencing agent vutrisiran, resulting in clinical stabilization and biomarker improvement. DISCUSSION: This case highlights nonbiopsy diagnosis of hATTR cardiomyopathy and escalation to gene-silencing therapy when progression occurs despite stabilizer therapy. TAKE-HOME MESSAGES: Val142Ile hATTR should be considered in patients with HFpEF, atrial arrhythmias, and increased ventricular wall thickness. Progression despite tafamidis warrants reassessment and consideration of gene-silencing therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.